NFATc3 mediates chronic hypoxia-induced pulmonary arterial remodeling with alpha-actin up-regulation
about
Understanding the pathogenesis of Kawasaki disease by network and pathway analysisHuman Tubal-Derived Mesenchymal Stromal Cells Associated with Low Level Laser Therapy Significantly Reduces Cigarette Smoke-Induced COPD in C57BL/6 miceNuclear factor of activated T cells regulates osteopontin expression in arterial smooth muscle in response to diabetes-induced hyperglycemia.PPARγ attenuates hypoxia-induced hypertrophic transcriptional pathways in the heart.The protective effects of PCPA against monocrotaline-induced pulmonary arterial hypertension are mediated through the downregulation of NFAT-1 and NF-κBIntegrated transcriptomic response to cardiac chronic hypoxia: translation regulators and response to stress in cell survival.Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapiesIsoform- and tissue-specific regulation of the Ca(2+)-sensitive transcription factor NFAT in cardiac myocytes and heart failure.NFATc3 contributes to intermittent hypoxia-induced arterial remodeling in miceAsthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis?Mechanisms of NFATc3 activation by increased superoxide and reduced hydrogen peroxide in pulmonary arterial smooth muscle.MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cellsThe α and Δ isoforms of CREB1 are required to maintain normal pulmonary vascular resistance.Endothelin-1 contributes to increased NFATc3 activation by chronic hypoxia in pulmonary arteries.NFATc3 is required for chronic hypoxia-induced pulmonary hypertension in adult and neonatal miceGalangin attenuates airway remodelling by inhibiting TGF-β1-mediated ROS generation and MAPK/Akt phosphorylation in asthmaUpregulation of osmo-mechanosensitive TRPV4 channel facilitates chronic hypoxia-induced myogenic tone and pulmonary hypertensionMechanical Stretch Inhibits MicroRNA499 via p53 to Regulate Calcineurin-A Expression in Rat CardiomyocytesResveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscleNFATc3 and VIP in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary DiseaseMesenchymal stem cells suppress CaN/NFAT expression in the pulmonary arteries of rats with pulmonary hypertensionMesenchymal stem cell-conditioned media suppresses inflammation-associated overproliferation of pulmonary artery smooth muscle cells in a rat model of pulmonary hypertension.Regulation of ca(2+) signaling in pulmonary hypertension.Silencing of STIM1 attenuates hypoxia-induced PASMCs proliferation via inhibition of the SOC/Ca2+/NFAT pathwayMolecular mechanisms of chronic intermittent hypoxia and hypertensionNFAT is required for spontaneous pulmonary hypertension in superoxide dismutase 1 knockout mice.Regulation of de novo ceramide synthesis: the role of dihydroceramide desaturase and transcriptional factors NFATC and Hand2 in the hypoxic mouse heartASIC1-mediated calcium entry stimulates NFATc3 nuclear translocation via PICK1 coupling in pulmonary arterial smooth muscle cellsRegulation of soluble guanylyl cyclase-alpha1 expression in chronic hypoxia-induced pulmonary hypertension: role of NFATc3 and HuR.Regulation of nuclear factor of activated T cells (NFAT) in vascular endothelial cells.Intermittent hypoxia-induced increases in reactive oxygen species activate NFATc3 increasing endothelin-1 vasoconstrictor reactivity.Reactive oxygen species in pulmonary vascular remodeling.IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling.Mechanisms of intermittent hypoxia induced hypertension.Endothelin-1-induced vasoconstriction does not require intracellular Ca²⁺ waves in arteries from rats exposed to intermittent hypoxia.New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation.Anticipated classes of new medications and molecular targets for pulmonary arterial hypertensionVascular smooth muscle cell phenotype is defined by Ca2+-dependent transcription factors.The role of nuclear factor of activated T cells in pulmonary arterial hypertension.Inhibition of SOC/Ca2+/NFAT pathway is involved in the anti-proliferative effect of sildenafil on pulmonary artery smooth muscle cells.
P2860
Q26996702-B49BBB40-45ED-44D9-B03C-5A5913677E58Q27320712-342F3168-9768-49B1-A43A-BD72CB295632Q30433306-30859EBB-2A48-47B2-A5D1-6217E80ACE73Q33738569-81DF6B4D-9CD3-422A-8911-02A5EBB75413Q33783941-7479120A-1537-4334-B9B0-56F2AB251B71Q33799336-4627AEB3-DB4A-4CA8-99D6-2E028C87E38BQ33849207-59BB0E2D-896F-4331-B130-27F362489494Q33917101-C2B3D01D-1802-4D04-8855-38086C83C95BQ34092840-5460B2F1-2C7E-457A-B82E-8CCFA6A2A782Q34235628-7103BC92-0D2A-46BF-9101-CC3A85DCA06AQ34519078-CEDAFDE2-F0BE-4FA1-9BF4-9246DA2A9925Q34818972-605000D5-8AC3-468B-B54A-50E9386AB29AQ35069403-4BBAA232-5F45-4D22-B35C-BC3429A0C1C2Q35159459-5FF98BB5-BDB8-4B4A-A39E-E832065B66ACQ35601485-DB358574-CFD0-41D2-9B46-9F3869DD81E2Q35834096-54EF97DD-0EBF-4ADA-8BB6-3FFCCC1FAEB0Q35850305-A0F018F5-9907-445A-A391-D2DCD55A81C4Q35918043-198487DF-7E50-4A46-AEA6-EF34782F2DC6Q36018374-86F70DAD-95BA-4458-9CBE-F5155BA751A1Q36261127-6A960E5D-D3F9-49FC-AAA0-97C61D91FB33Q36336333-623D272E-B879-4F87-A220-E2F98FF87D58Q36524066-BF4BCE36-9DCD-4D2A-9547-B97BECFCC399Q36628777-6EB2B772-9E2C-4828-A426-A22A76687476Q36689869-17C56376-2617-4943-8B68-87ECABDC5A3EQ36790835-66DAEB9A-B5DB-4767-A654-BF7B0FF340B0Q36837739-A9B91CD3-FF64-4D9E-B7E0-F51B4A42404DQ36880116-D54E4C0F-1377-4A7C-90ED-2E1592ADC79CQ37139574-76006730-30DE-4AFB-B788-847662D34D99Q37337510-213EE19E-7B52-433E-9ADD-2A70986CEC86Q37426782-778D3CDB-1196-4F71-B409-4D5E18AF8FFFQ37519229-8D5BA56D-7530-4A19-933A-351040DB82ECQ37532988-04CBDD19-2D29-4629-8C57-B8ADDF2883C1Q37594217-9B7812CA-3FE0-494E-A261-83C3BDF1F32BQ37612046-BC824304-E012-4C29-A999-53C1D03BBB76Q37629265-5AB2A3B2-E363-48D5-BAF1-819D22CEE0ACQ37724192-2FE0B7B4-83AD-4CF1-B45F-95C9124F0741Q38105550-023161E1-E16D-4CA2-AACA-67726C619985Q38121164-7F9D53B9-F7FB-4F55-8403-9D4CF97283A2Q39095141-AAAD107D-C385-4614-8D54-156F4F078C3FQ39911609-26E64EE3-2E80-435F-A843-C8281E28C6C0
P2860
NFATc3 mediates chronic hypoxia-induced pulmonary arterial remodeling with alpha-actin up-regulation
description
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique Journal of Biological Chemistry
@fr
artículu científicu espublizáu en 2007
@ast
im Mai 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2007/05/18)
@sk
vědecký článek publikovaný v roce 2007
@cs
wetenschappelijk artikel (gepubliceerd op 2007/05/18)
@nl
наукова стаття, опублікована в травні 2007
@uk
name
NFATc3 mediates chronic hypoxi ...... with alpha-actin up-regulation
@ast
NFATc3 mediates chronic hypoxi ...... with alpha-actin up-regulation
@en
NFATc3 mediates chronic hypoxi ...... with alpha-actin up-regulation
@nl
type
label
NFATc3 mediates chronic hypoxi ...... with alpha-actin up-regulation
@ast
NFATc3 mediates chronic hypoxi ...... with alpha-actin up-regulation
@en
NFATc3 mediates chronic hypoxi ...... with alpha-actin up-regulation
@nl
prefLabel
NFATc3 mediates chronic hypoxi ...... with alpha-actin up-regulation
@ast
NFATc3 mediates chronic hypoxi ...... with alpha-actin up-regulation
@en
NFATc3 mediates chronic hypoxi ...... with alpha-actin up-regulation
@nl
P2093
P2860
P356
P1476
NFATc3 mediates chronic hypoxi ...... with alpha-actin up-regulation
@en
P2093
Dominique Alò
Laura V. González Bosc
Rhyannon Spangler
Sergio de Frutos
P2860
P304
15081–15089
P356
10.1074/JBC.M702679200
P407
P577
2007-05-18T00:00:00Z